David Ulises Garibay-Trevino

David Ulises Garibay-Trevino

Auto-generated profile, based on publicly available information

David Ulises Garibay-Trevino

School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Medical Decision Making
Verified
Journal Article
Open access
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
HJHawre Jalal
Hawre Jalal
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
Purpose. Individual-level simulation models often require sampling times to events; however, efficient parametric distributions for many processes may often not exist. For example, time to death from life tables cannot be accurately sampled from existing parametric distributions. We propose an efficient nonparametric method to sample times to events that does not require any parametric assumption on the hazards. Methods. We developed a nonparametric sampling (NPS) approach that simultaneously draws multiple time-to-event samples from a categorical distribution. This approach can be applied to univariate and multivariate processes. We discretize the entire period into equal-length time intervals and then derived the interval-specific probabilities. The times to events can then be used directly in individual-level simulation models. We compared the accuracy of our approach in sampling time-to-events from common parametric distributions, including exponential, gamma, and Gompertz. In addition, we evaluated the method’s performance in sampling age to death from US life tables and sampling times to events from parametric baseline hazards with time-dependent covariates. Results. The NPS method estimated similar expected times to events from 1 million draws for the 3 parametric distributions, 100,000 draws for the homogenous cohort, 200,000 draws from the heterogeneous cohort, and 1 million draws for the parametric distributions with time-varying covariates, all in less than 1 second. Conclusion. Our method produces accurate and computationally efficient samples for time to events from hazards without requiring parametric assumptions. Highlights: The nonparametric sampling method is generic and can sample times to an event from any discrete (or discretizable) hazard without requiring any parametric assumption. The method is showcased with 5 commonly used distributions in discrete-event simulation models. The method produced very similar expected times to events, as well as their probability distribution, compared with analytical results. We provide a multivariate categorical sampling function for R and Python programming languages to sample times to events from processes with different hazards simultaneously.

11 July 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Background: Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available from the SEER Program upon request) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable. Methods: Using SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed from 1992 to 2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC third edition for 1992–2003, Derived AJCC sixth edition for 2004–2015, Derived SEER Combined for 2016–2017, and Derived EOD 2018 for 2018–2019). We used joinpoint regression to analyze changes in trends. Results: The data availability has improved with the revised staging system as the proportion of cases with missing lymph node and metastasis stages was substantially reduced. However, the trends varied by tumor stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992. Conclusions: With the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends seem smoother. Impact: Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.

2 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
PKPraveen Kumar
Praveen Kumar
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
TCTanvi V Chiddarwar
Tanvi V Chiddarwar
DGDavid Ulises Garibay-Treviño
David Ulises Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Purpose: Bladder cancer is associated with significant morbidity and mortality in the US, with 85,000 new cases and 17,400 deaths expected in 2025. Black patients are more likely than White patients to be diagnosed with bladder cancer at advanced stages, as are female patients compared with male patients. We examine whether differences in cancer diagnosis rates by race and sex can explain the observed variability using a simulation model and project outcomes of potential improvement in diagnosis. Methods: We developed a state transition model for bladder cancer to simulate four cohorts based on sex (males, females) and race (Blacks, Whites) from birth through various health states, including disease-free, preclinical stages (0a/0is - IV), clinical stages (0a/0is - IV), and death (bladder cancer or other cause death). Parameters related to disease onset, progression, and diagnosis were estimated by calibrating the model to race- and sex-specific incidence rates by age, and stage distribution at diagnosis for cases diagnosed between 2015 and 2019 in SEER 17 registry areas. We conducted a scenario analysis to examine the impact of differences in diagnosis rates on stage distribution and life expectancy, assuming that Black males (or females) and White females had diagnosis rates similar to those of White males. Results: The calibrated model attributes the differences in stage distribution to lower diagnosis rates in White females (hazard ratio, [HR] = 0.95, 95% credible interval [CI]: 0.92 - 0.96), Black males (0.80, 95% CI: 0.75 - 0.81) and Black females (0.56, 95% CI: 0.53 - 0.58), relative to White males. If diagnosis rates for all demographic groups were similar to White males, the expected life span of a 65-year-old bladder cancer patient would increase by 0.2 years for White females (from 13.8 to 13.9 years), 0.6 years for Black males (from 10.6 to 11.1 years), and 1.9 years for Black females (from 10.5 to 12.4 years). Conclusions: Differences in diagnosis rates of bladder cancer by race and sex explain the observed differences in stage distribution at diagnosis. Targeted interventions aimed at improving diagnosis rates have the potential to substantially improve survival for patients with bladder cancer.

2 September 2025
Verified
Other
Open access
PDF file
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Supplementary Table S1 shows mapping of TNM stages as per the consistent disease definition of bladder cancer

30 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
HJHawre Jalal
Hawre Jalal
SKStella K. Kang
Stella K. Kang
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
SCStavroula A. Chrysanthopoulou
Stavroula A. Chrysanthopoulou
DGDavid Ulises Garibay-Trevino
David Ulises Garibay-Trevino
TTThomas A. Trikalinos
Thomas A. Trikalinos
Background: Bladder cancer imposes substantial clinical and economic burden, yet key natural-history quantities that determine the potential effectiveness of screening—such as the size of the screen-detectable preclinical reservoir and the preclinical sojourn time—are largely unobservable. The Cancer Intervention and Surveillance Modeling Network (CISNET) uses standardized stress tests to compare independently developed microsimulation models and to clarify how differences in model structure translate into differences in intervention impact. The Maximum Clinical Incidence Reduction (MCLIR) framework estimates the maximum achievable reduction in clinically detected incidence following a one-time, perfect screening intervention, while Realistic Clinical Incidence Reduction (RCLIR) relaxes the perfect-test and/or perfect-treatment assumptions. Methods: We applied the CISNET MCLIR/RCLIR protocol to three independently developed bladder cancer microsimulation models (COBRAS, Kystis, and SCOUT), each calibrated to common U.S. epidemiologic targets. We simulated a U.S. birth cohort born in 1950 and compared: (1) no-screening baseline; (2) one-time perfect screening with universally curative treatment (MCLIR) at ages 60, 65, 70, and 75; and (3) one-time realistic screening with cystoscopy sensitivity of 80% and perfect treatment (RCLIR-1) or usual-care treatment effectiveness (RCLIR-2). Outcomes included age-specific clinical incidence and incidence-reduction curves relative to baseline, as well as cumulative reductions over follow-up. Results: Across models, median ages at first lesion emergence, clinical diagnosis, and onset of muscle-invasive disease were similar, but preclinical sojourn time differed meaningfully: COBRAS produced the shortest median sojourn time (2.1 years) compared with Kystis (3.3 years) and SCOUT (3.1 years). Under MCLIR, all models predicted an immediate drop in clinical incidence followed by attenuation toward zero as new lesions emerged after the screening age. Peak MCLIR at age 65 among White men ranged from 20% (COBRAS) to 21% (Kystis) and 32% (SCOUT), with reductions dissipating within ∼8 years in COBRAS and persisting ∼10 years in Kystis and SCOUT. In COBRAS and Kystis, incidence reductions later became negative, consistent with rebound emergence of new lesions among individuals whose first lesions were removed by screening. Under RCLIR-1, peak reductions were smaller and varied substantially across models (13%, 4%, and 37% for COBRAS, Kystis, and SCOUT, respectively). RCLIR-2 further reduced gains and produced more gradual decay, reflecting incomplete prevention under usual-care treatment. Across models, most residual post-screening incidence was attributable to new lesion emergence rather than missed detection or incomplete treatment. Conclusions: In a standardized CISNET stress test, three bladder cancer microsimulation models imply a relatively short detectable preclinical phase, placing a modest upper bound on the effectiveness of one-time screening in the general population. Differences in MCLIR/RCLIR magnitude and persistence are explained by differences in implied sojourn time and detectable reservoir size. These findings motivate evaluation of risk-targeted and repeated early-detection strategies and highlight key empirical priorities for improving inference on bladder cancer natural history.

2 September 2025
Verified
Other
Open access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Supplementary Figure S2 shows the comparison of age-adjusted incidence rates by M stage between the original and revised staging variables, using JoinPoint Regression Analysis.